Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commissioner Choice Appears To Be Crawford

This article was originally published in The Pink Sheet Daily

Executive Summary

The White House appears to have settled on Acting Commissioner Lester Crawford to fill the agency's top slot permanently. Crawford is understood to have met with President Bush Jan. 27.

The White House appears to have settled on FDA Acting Commissioner Lester Crawford as its choice to fill the commissioner slot on a permanent basis.

Crawford is understood to have met with President Bush Jan. 27, suggesting that an announcement could come at any time.

Crawford is said to have the support of a number of key senators, including Utah Republican Orrin Hatch. With the confirmation of former Utah Gov. Michael Leavitt as HHS secretary, Hatch's support is particularly important.

Crawford has been the acting head of FDA since Mark McClellan left the agency to take over the Centers for Medicare & Medicaid Services last spring.

- Michael McCaughan

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel